Health-related quality of life during adjuvant treatment for breast cancer among postmenopausal women
Health-related quality of life during adjuvant treatment for breast cancer among postmenopausal women
复制标题
DOI：
10.1016/j.ejon.2008.01.005
复制
发表时间：
2008-07-01
影响因子：
2.8
通讯作者：
Gaston-Johansson, Fannie
中科院分区：
文献类型：
--
作者：
Browall, Maria;Ahlberg, Karin;Gaston-Johansson, Fannie
本研究的目的有两个：第一，描述绝经后乳腺癌女性辅助治疗期间健康相关生活质量（HRQoL）的变化;第二，在同一人群中，从基线时测量的感知功能、症状、情绪困扰和临床/人口统计学变量中确定治疗后总体生活质量（QoL）的最佳预测因子。研究组为150名女性（≥ 55岁），计划接受辅助化疗（CT，n=75）或放疗（RT，n=75）。他们在治疗前（基线）、治疗期间和治疗完成后接受检查。使用欧洲癌症研究和治疗组织（EORTC）-QLQ-C30，BR 23和医院焦虑和抑郁量表（HADS）问卷收集有关QoL，感知功能，症状和情绪困扰的数据。一般结果是，辅助治疗与总体QoL、身体和角色功能、焦虑和身体形象下降以及随时间推移测量的疲乏、呼吸困难、疼痛、恶心/呕吐、便秘和全身治疗副作用增加相关。对于接受CT的女性，基线时情绪功能更好和疼痛更少预示着治疗结束时总体生活质量更好。对于接受RT的女性，更好的身体和情感功能，更少的乳腺症状和基线时较低的肿瘤分期预测治疗结束时更好的总体生活质量。(c)2008爱思唯尔有限公司保留所有权利。
The purpose of the present study was twofold: first, to describe changes of Health-Related Quality of Life (HRQoL) during the adjuvant treatment among postmenopausal women with breast cancer; second, in the same population to identify the best predictors of Overall Quality of Life (QoL) after treatment, from perceived functioning, symptoms, emotional distress and clinical/demographic variables measured at baseline. The study group was 150 women (>= 55 years of age) scheduled for adjuvant chemotherapy (CT, n=75) or radiotherapy (RT, n=75). They were examined before (baseline), during and after completing the treatment. Data about QoL, perceived functioning, symptoms and emotional distress were collected with the European Organisation for Research and Treatment of Cancer (EORTC)-QLQ-C30, BR23 and Hospital Anxiety and Depression Scale (HADS) questionnaires. The general finding was that the adjuvant treatments were associated with decrease in overall QoL, physical and role functioning, anxiety and body image, as well as with increase in fatigue, dyspnoea, pain, nausea/vomiting, constipation and systemic therapy side effects measured over time. For women receiving CT, better emotional functioning and less pain at baseline predicted better overall QoL at the end of the treatment. For women receiving RT, better physical and emotional functioning, less breast symptoms and lower tumour stage at baseline predicted better overall QoL at the end of the treatment. (c) 2008 Elsevier Ltd. All rights reserved.